XLO insider transactions

SEC Form 4 filed by Director Shannon James Samuel

SEC Form 4 filed by Director Bonstein Sara

SEC Form 4 filed by Director Curran Daniel J.

SEC Form 4 filed by Director Xu Yuan

SEC Form 4 filed by Director Ross Robert W.

SEC Form 4 filed by Director Bello Akintunde Olatokumbo

SEC Form 4 filed by Director Brennan Aoife

SEC Form 4 filed by Blanchard Cheryl R

SEC Form 3 filed by new insider Blanchard Cheryl R

SEC Form 4 filed by Shannon James Samuel

SEC Form 4 filed by Large owner Gilead Sciences, Inc.

CHIEF MEDICAL OFFICER Luptakova Katarina converted options into 16,625 shares, increasing direct ownership by 100% to 33,250 units (SEC Form 4)

Chief Financial Officer Frankenfield Christopher James converted options into 19,375 shares and sold $4,522 worth of shares (7,030 units at $0.64), increasing direct ownership by 99% to 24,766 units (SEC Form 4)

SVP, FINANCE AND ACCOUNTING Brennan Kevin M. converted options into 5,000 shares and sold $1,174 worth of shares (1,826 units at $0.64), increasing direct ownership by 99% to 6,371 units (SEC Form 4)

PRESIDENT AND CEO Russo Rene converted options into 44,250 shares, increasing direct ownership by 16% to 325,422 units (SEC Form 4)

SEC Form 4 filed by Xilio Therapeutics Inc.

SEC Form 4 filed by SVP, FINANCE AND ACCOUNTING Brennan Kevin M.

SEC Form 4 filed by Chief Financial Officer Frankenfield Christopher James

SEC Form 4 filed by CHIEF MEDICAL OFFICER Luptakova Katarina

SEC Form 4 filed by PRESIDENT AND CEO Russo Rene

Director Shannon James Samuel bought $48,085 worth of shares (70,000 units at $0.69) (SEC Form 4)

PRESIDENT AND CEO Russo Rene bought $24,680 worth of shares (36,289 units at $0.68), increasing direct ownership by 15% to 281,172 units (SEC Form 4)

Amendment: SEC Form 4 filed by PRESIDENT AND CEO Russo Rene

SEC Form 4 filed by Director Ross Robert W.

SEC Form 4 filed by Director Brennan Aoife

SEC Form 4 filed by Director Bonstein Sara

SEC Form 4 filed by Director Curran Daniel J.

SEC Form 4 filed by Director Clancy Paul J

SEC Form 4 filed by Director Xu Yuan

SEC Form 4 filed by Director Shannon James Samuel

SEC Form 4 filed by Director Rossi Christina

SEC Form 4 filed by Director Bello Akintunde Olatokumbo

SEC Form 3 filed by new insider Bello Akintunde Olatokumbo

SEC Form 4 filed by Large owner Gilead Sciences, Inc.

SEC Form 4 filed by Chief Financial Officer Frankenfield Christopher James

SEC Form 4 filed by PRESIDENT AND CEO Russo Rene

Chief Financial Officer Frankenfield Christopher James converted options into 19,375 shares and sold $6,841 worth of shares (6,954 units at $0.98) (SEC Form 4)

SVP, FINANCE AND ACCOUNTING Brennan Kevin M. converted options into 5,000 shares and sold $1,774 worth of shares (1,803 units at $0.98) (SEC Form 4)

PRESIDENT AND CEO Russo Rene converted options into 44,250 shares, increasing direct ownership by 22% to 244,883 units (SEC Form 4)

CHIEF MEDICAL OFFICER Luptakova Katarina converted options into 16,625 shares (SEC Form 4)

Large owner Gilead Sciences, Inc. bought $1,830,377 worth of shares (1,759,978 units at $1.04), increasing direct ownership by 24% to 9,105,451 units (SEC Form 4)

SEC Form 4 filed by SVP, FINANCE AND ACCOUNTING Brennan Kevin M.

New insider Chudnovsky Yekaterina claimed ownership of 7,000,000 shares (SEC Form 3)

SEC Form 4 filed by Chief Operating Officer Frankenfield Christopher James

SEC Form 4 filed by Director Clancy Paul J

SEC Form 4 filed by Director Bonstein Sara

SEC Form 4 filed by Director Xu Yuan

SEC Form 4 filed by Director Rossi Christina

SEC Form 4 filed by Director Curran Daniel J.

SEC Form 4 filed by Director Ross Robert W.

SEC Form 4 filed by Director Shannon James Samuel

SEC Form 3 filed by new insider Shannon James Samuel

SEC Form 4 filed by Director Brennan Aoife

SEC Form 3 filed by new insider Brennan Aoife

SEC Form 4 filed by Frankenfield Christopher James

SEC Form 4 filed by Luptakova Katarina

SEC Form 4 filed by Brennan Kevin M.

SEC Form 4 filed by Russo Rene

Gilead Sciences, Inc. bought $368,790 worth of shares (485,250 units at $0.76), increasing direct ownership by 7% to 7,345,473 units (SEC Form 4)

New insider Gilead Sciences, Inc. claimed ownership of 6,860,223 shares (SEC Form 3)